Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps.
Biomarkers
Chronic rhinosinusitis with nasal polyps
Diagnostic tool
Nasal cytology
Type-2 inflammation
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
28
01
2022
revised:
23
08
2022
accepted:
26
08
2022
entrez:
2
11
2022
pubmed:
3
11
2022
medline:
3
11
2022
Statut:
epublish
Résumé
The identification of type-2 inflammation in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) acquires a crucial role in the endotypization needed for selecting patients for biological drugs targeting type-2 inflammation: to date, the parameters used include systemic and histological biomarkers. The aim of this study was to investigate whether nasal cytology could identify type-2 inflammation in patients with CRSwNP. Thirty-three consecutive patients with CRSwNP underwent nasal cytology sampling at the level of the lower nasal turbinate, and of the polypoid tissue, and surgical polyp tissue sample was collected. The cellularity of the 3 collected samples were compared. Mean nasal polyp tissue, nasal polyps cytology and inferior turbinate cytology eosinophils counts were 43.7 ± 39.6 cells/HPF, 32.8 ± 44.7 cells/HPF and 27.6 ± 58.0 cells/HPF respectively with inferior turbinate cytology eosinophils significantly lower than nasal polyp tissue count (p = 0.007). Both mean nasal polyps cytology eosinophils and mean inferior turbinate cytology eosinophils were significantly higher in patients with type-2 CRSwNP (52.5 ± 67.0 cells/HPF vs 12.2 ± 17.3 cells/HPF, p = 0.012, and 32.0 ± 62.1 cells/HPF vs 2.9 ± 2.9 cells/HPF, p = 0.020 respectively). Nasal cytology is suitable tool for assessing local biomarkers of type-2 inflammation in CRSwNP.
Sections du résumé
Background
UNASSIGNED
The identification of type-2 inflammation in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) acquires a crucial role in the endotypization needed for selecting patients for biological drugs targeting type-2 inflammation: to date, the parameters used include systemic and histological biomarkers. The aim of this study was to investigate whether nasal cytology could identify type-2 inflammation in patients with CRSwNP.
Methodology
UNASSIGNED
Thirty-three consecutive patients with CRSwNP underwent nasal cytology sampling at the level of the lower nasal turbinate, and of the polypoid tissue, and surgical polyp tissue sample was collected. The cellularity of the 3 collected samples were compared.
Results
UNASSIGNED
Mean nasal polyp tissue, nasal polyps cytology and inferior turbinate cytology eosinophils counts were 43.7 ± 39.6 cells/HPF, 32.8 ± 44.7 cells/HPF and 27.6 ± 58.0 cells/HPF respectively with inferior turbinate cytology eosinophils significantly lower than nasal polyp tissue count (p = 0.007). Both mean nasal polyps cytology eosinophils and mean inferior turbinate cytology eosinophils were significantly higher in patients with type-2 CRSwNP (52.5 ± 67.0 cells/HPF vs 12.2 ± 17.3 cells/HPF, p = 0.012, and 32.0 ± 62.1 cells/HPF vs 2.9 ± 2.9 cells/HPF, p = 0.020 respectively).
Conclusions
UNASSIGNED
Nasal cytology is suitable tool for assessing local biomarkers of type-2 inflammation in CRSwNP.
Identifiants
pubmed: 36321070
doi: 10.1016/j.waojou.2022.100700
pii: S1939-4551(22)00076-X
pmc: PMC9587370
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100700Informations de copyright
© 2022 The Author(s).
Références
Laryngoscope. 2017 Mar;127(3):550-555
pubmed: 27859303
J Allergy Clin Immunol. 2016 Nov;138(5):1344-1353
pubmed: 27544740
Allergy Asthma Proc. 1996 Sep-Oct;17(5):243-9
pubmed: 8922143
Lancet. 2019 Nov 2;394(10209):1638-1650
pubmed: 31543428
Allergy. 2022 Jan;77(1):150-161
pubmed: 33978983
World Allergy Organ J. 2019 Jan 26;12(1):100007
pubmed: 30937132
Allergy. 2019 Dec;74(12):2312-2319
pubmed: 31090937
Respir Res. 2018 Jun 27;19(1):129
pubmed: 29945606
J Allergy Clin Immunol. 2021 Jan;147(1):29-36
pubmed: 33227318
Allergy. 2019 Jan;74(1):28-39
pubmed: 30216468
Clin Exp Allergy. 2018 Sep;48(9):1092-1106
pubmed: 29904978
Allergol Int. 2021 Jul;70(3):370-372
pubmed: 33358385
Ann Otol Rhinol Laryngol. 2003 Jul;112(7):625-9
pubmed: 12903683
Otolaryngol Head Neck Surg. 2006 Nov;135(5 Suppl):S31-80
pubmed: 17081855
Laryngoscope. 2019 Sep;129(9):1969-1975
pubmed: 30720213
Nat Rev Immunol. 2021 Nov;21(11):739-751
pubmed: 33846604
Expert Rev Clin Immunol. 2018 Sep;14(9):731-737
pubmed: 30107759
J Allergy Clin Immunol. 2020 Sep;146(3):595-605
pubmed: 32524991
Allergy. 2021 Aug;76(8):2337-2353
pubmed: 33683704
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620965151
pubmed: 33263506
J Asthma Allergy. 2020 Dec 31;13:743-752
pubmed: 33408487
Ann Otol Rhinol Laryngol. 2011 Jul;120(7):423-7
pubmed: 21859049
J Biol Regul Homeost Agents. 2009 Jul-Sep;23(3):181-8
pubmed: 19828095
Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):373-378
pubmed: 31135395
Am J Rhinol Allergy. 2010 Nov-Dec;24(6):413-5
pubmed: 21144220
Rhinology. 2020 Feb 20;58(Suppl S29):1-464
pubmed: 32077450
Annu Rev Immunol. 2021 Apr 26;39:719-757
pubmed: 33646859
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211009398
pubmed: 33910399
Am J Rhinol Allergy. 2021 Jan;35(1):77-85
pubmed: 32564684
Lancet Respir Med. 2021 Oct;9(10):1141-1153
pubmed: 33872587
Respir Med. 2020 May;166:105947
pubmed: 32250875
Eur Arch Otorhinolaryngol. 2022 Jun 6;:
pubmed: 35666318
J Allergy Clin Immunol. 2022 Apr;149(4):1309-1317.e12
pubmed: 34599979
J Allergy Clin Immunol. 2020 Mar;145(3):740-750
pubmed: 32145873
Int Forum Allergy Rhinol. 2017 Sep;7(9):861-867
pubmed: 28665504
J Allergy Clin Immunol. 1977 Jan;59(1):17-21
pubmed: 833373
J Allergy Clin Immunol. 2002 Apr;109(4):621-6
pubmed: 11941310
J Laryngol Otol. 1999 Nov;113(11):983-7
pubmed: 10696375
BMJ Case Rep. 2020 Apr 2;13(4):
pubmed: 32245837
Acta Otorhinolaryngol Ital. 2020 Oct;40(5):368-376
pubmed: 33299227